John Gillen
CEO & Director
For the past two decades John Gillen has dedicated his life to exploring the latest NAD+ (Nicotinamide Adenine Dinucleotide) therapies, delivering cutting-edge treatments to the UK and across Europe.
For the past two decades John Gillen has dedicated his life to exploring the latest NAD+ (Nicotinamide Adenine Dinucleotide) therapies, delivering cutting-edge treatments to the UK and across Europe.
For the past two decades John Gillen has dedicated his life to exploring the latest NAD+ (Nicotinamide Adenine Dinucleotide) therapies, delivering cutting-edge treatments to the UK and across Europe.
A true pioneer in the quest for innovative therapies for mental wellness and addiction recovery, John prides himself on working with the very best medical professionals in the field, with the purpose of providing game-changing treatments to those in need.
John’s latest venture sees him the opening of the brand new Eula’s Clinic in Scotland, specialising in offering ground-breaking scientifically backed psychedelic-assisted psychotherapy treatment.
The driving force behind our company's vision and mission
While traditional talk therapy can be effective for many people, there is growing interest in exploring alternative forms of therapy that involve the use of mind-altering substances. Two such substances that are currently being explored for their therapeutic potential are MDMA and Ketamine. Read more
Discover the science behind ketamine and its use in psychotherapy. Explore how this emerging field is changing mental health treatment Read more